Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
8 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Whitehawk Therapeutics, Inc.’s names, not what it holds today.
Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
23
since 2001, to Dec 31, 2025
Names they are printed under
2
a former name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Aerpio Pharmaceuticals, Inc. a former name
named as the applicant on its applications, in US
23 publishedAERPIO PHARMACEUTICALS, INC. a former name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Oct 5, 2021 | 11,136,389 | Humanized monoclonal antibodies that target VE-PTP (HPTP-β) | Pharmaceuticals | AERPIO PHARMACEUTICALS, INC. |
| Mar 23, 2021 | 10,952,992 | Methods of treating intraocular pressure with activators of Tie-2 | Pharmaceuticals | AERPIO PHARMACEUTICALS, INC. |
| Jan 19, 2021 | 10,894,824 | Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF | Biotechnology | AERPIO PHARMACEUTICALS, INC. |
| Dec 8, 2020 | 10,858,354 | HPTP-Beta inhibitors | Pharmaceuticals | AERPIO PHARMACEUTICALS, INC. |
| Oct 27, 2020 | 10,815,300 | Methods for treating vascular leak syndrome and cancer | Pharmaceuticals | AERPIO PHARMACEUTICALS, INC. |
| Mar 31, 2020 | 10,604,569 | Humanized monoclonal antibodies that target protein tyrosine phosphatase-beta (HPTP-β/VE-PTP) | Pharmaceuticals | AERPIO PHARMACEUTICALS, INC. |
| Mar 24, 2020 | 10,597,452 | Methods of treating ocular conditions by administering humanized monoclonal antibodies that target VE-PTP (HPTP-beta) | Pharmaceuticals | AERPIO PHARMACEUTICALS, INC. |
| Nov 5, 2019 | 10,463,650 | Human protein tyrosine phosphatase inhibitors and methods of use | Pharmaceuticals | AERPIO PHARMACEUTICALS, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Sep 12, 2024 | 2024/0299367 | METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME WITH ACTIVATORS OF TIE-2 | Pharmaceuticals | Aerpio Pharmaceuticals, Inc. |
| Apr 21, 2022 | 2022/0117946 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | Pharmaceuticals | Aerpio Pharmaceuticals, Inc. |
| Jan 20, 2022 | 2022/0016086 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | Pharmaceuticals | Aerpio Pharmaceuticals, Inc. |
| Dec 16, 2021 | 2021/0386713 | METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 | Pharmaceuticals | Aerpio Pharmaceuticals, Inc. · patent 11,666,558 granted from it |
| Jul 15, 2021 | 2021/0212998 | Combinations of Tie-2 Activators and Prostaglandins and Uses Thereof | Pharmaceuticals | Aerpio Pharmaceuticals, Inc. |
| Jun 10, 2021 | 2021/0171618 | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF | Biotechnology | Aerpio Pharmaceuticals, Inc. · patent 11,873,334 granted from it |
| May 20, 2021 | 2021/0147404 | SMALL MOLECULE ACTIVATORS OF TIE-2 | Organic fine chemistry | Aerpio Pharmaceuticals, Inc. · patent 11,613,534 granted from it |
| May 6, 2021 | 2021/0130341 | HPTP-BETA INHIBITORS | Pharmaceuticals | Aerpio Pharmaceuticals, Inc. |
| Apr 1, 2021 | 2021/0095017 | METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER | Pharmaceuticals | Aerpio Pharmaceuticals, Inc. · patent 12,043,664 granted from it |
| Dec 31, 2020 | 2020/0407430 | ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF | Pharmaceuticals | Aerpio Pharmaceuticals, Inc. · patent 11,814,425 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.